Laboratory stock photograph: Trnava University / Unsplash.
Collagen-targeted MRI could change what cancer scans reveal by looking for the structural material around a tumour.
Researchers have developed an experimental MRI contrast agent that homes in on the structural material around tumours. In animal experiments, it helped reveal tiny lung cancers and small deposits of cancer in other organs. Reuters highlighted the work on 16 September 2026, following its publication in Science Advances. This is preclinical research, not a new test available to patients. Reuters report
Following cancer’s scaffolding
A contrast agent is a substance that makes particular tissues easier to distinguish on a scan. This protein-based agent, called hProCA32.Collagen, targets collagen I: part of the body’s supporting framework that can build up and reorganise around invasive cancers.
Think of it as looking for alterations to a building’s scaffolding rather than searching only for a change in its outline. The researchers are trying to turn a biological change around cancer into a more visible signal.
Georgia State University’s 9 September announcement describes detection of small tumours and cancer spread in the lungs, adrenal glands and kidneys. The approach also mapped features associated with invasion—the process by which cancer grows into surrounding tissue. Georgia State research announcement
The mouse results are the important part
The team examined tissue from 15 people with lung adenocarcinoma, a type of lung cancer, then tested the imaging approach in mouse models. Examining human tissue is not the same as giving the agent to patients.
In one model, MRI identified all 18 lung nodules subsequently confirmed by tissue examination, including some smaller than one millimetre. CT missed several of the smallest. That does not establish a 100% detection rate in people: it describes a particular animal experiment. Emory’s study summary
A clearer scan is not yet a better screening programme
Low-dose CT already has something this experimental approach lacks: evidence of fewer lung-cancer deaths in a large human screening trial. The National Lung Screening Trial enrolled more than 53,000 people at high risk and found approximately 15–20% fewer lung-cancer deaths with low-dose CT than with chest X-rays. National Cancer Institute
Screening also involves trade-offs. False positives can trigger unnecessary follow-up procedures, while overdiagnosis means finding cancers that would never have caused harm. Finding more abnormalities does not automatically improve people’s lives. CDC explanation of screening risks
For this new agent, the decisive questions therefore extend beyond the smallest visible spot: can it reliably distinguish dangerous disease, improve decisions and deliver benefits that outweigh its risks?
The next milestone is human testing
Georgia State says the researchers are working towards an investigational new drug application to enable clinical testing. InLighta BioSciences, founded by study co-leader Jenny Yang, has licensed related technology. That is a development pathway—not regulatory approval. Georgia State
Emory says additional safety work and regulatory review are needed before patient testing. It also discloses Yang’s InLighta shareholding and related patents. These interests deserve transparency alongside the findings. Emory
The compelling idea is to make cancer imaging more biologically informative. The challenge is proving that this extra information helps people—not merely that it produces an impressive scan.
Related: How prostate cancer’s DNA scars offer clues to its behaviour.
Leave a Reply